MYGN (Myriad Genetics) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MYGN Myriad Genetics Inc MYGN
42 GF Score
Price $3.97
GF Value $11.35
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Myriad Genetics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Myriad Genetics Valuation Rank Related Terms

MYGN
42GF Score
Myriad Genetics Inc MYGN
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Myriad Genetics (MYGN) Overvalued in 2026?

Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued. The current stock price of $3.97 is trading 65% below its estimated GF Value™ of $11.35. GuruFocus considers Myriad Genetics to be Possible Value Trap.

Key valuation signals for MYGN:

  • Valuation Rank:
  • GF Value™: $11.35 vs. price of $3.97 (65% below fair value)
  • GF Score™: 42/100 with 3 warning signs

No single metric tells the full story. See the MYGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Myriad Genetics Business Description

Other Exchanges 0K3W:UKMYD:Germany
Address 322 North 2200 West, Salt Lake City, UT, USA, 84116
Myriad Genetics Inc. is a US-based molecular diagnostics company that develops and commercializes genetic and genomic tests used across oncology, women's health, and mental health. Its portfolio includes hereditary cancer risk tests such as MyRisk and BRACAnalysis, tumor profiling and companion diagnostics including MyChoice CDx and Precise Tumor, the Prolaris prostate cancer test, the GeneSight pharmacogenomic test for depression and other psychiatric conditions, and the SneakPeek early fetal sex determination test. These tests are ordered by physicians, hospitals, health systems, and payers, and are used to assess disease risk, guide treatment selection, and inform reproductive decisions. Myriad generates revenue primarily through third-party reimbursement from insurers and government payers, along with direct patient billing. The company operates mainly in the United States, which accounts for the large majority of its revenue, and also sells in selected international markets.
42GF Score

Get the complete analysis for MYGN

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.97
Price
$11.35
GF Value